Johannessen CM, Johnson LA, Piccioni F, et al. A melanocyte lineage program confers resistance to MAP kinase pathway inhibition. Nature. 2013;504(7478):138-42. doi:10.1038/nature12688
Younger ST, Rinn JL. ’Lnc’-ing enhancers to MYC regulation. Cell Res. 2014;24(6):643-4. doi:10.1038/cr.2014.54
Giannakis M, Hodis E, Mu XJ, et al. RNF43 is frequently mutated in colorectal and endometrial cancers. Nat Genet. 2014;46(12):1264-6. doi:10.1038/ng.3127
Luo LY, Hahn WC. Oncogenic Signaling Adaptor Proteins. J Genet Genomics. 2015;42(10):521-9. doi:10.1016/j.jgg.2015.09.001
Cancer Genome Atlas Research Network, Kandoth C, Schultz N, et al. Integrated genomic characterization of endometrial carcinoma. Nature. 2013;497(7447):67-73. doi:10.1038/nature12113
Berger MF, Garraway LA. Applications of genomics in melanoma oncogene discovery. Hematol Oncol Clin North Am. 2009;23(3):397-414, vii. doi:10.1016/j.hoc.2009.03.005
Stegmaier K, Corsello SM, Ross KN, Wong JS, DeAngelo DJ, Golub TR. Gefitinib induces myeloid differentiation of acute myeloid leukemia. Blood. 2005;106(8):2841-8. doi:10.1182/blood-2005-02-0488
Choudhury AD, Eeles R, Freedland SJ, et al. The role of genetic markers in the management of prostate cancer. Eur Urol. 2012;62(4):577-87. doi:10.1016/j.eururo.2012.05.054
Yuan Y, Hartland K, Boskovic Z, et al. A small-molecule inducer of PDX1 expression identified by high-throughput screening. Chem Biol. 2013;20(12):1513-22. doi:10.1016/j.chembiol.2013.10.013
Konieczkowski DJ, Johannessen CM, Abudayyeh O, et al. A melanoma cell state distinction influences sensitivity to MAPK pathway inhibitors. Cancer Discov. 2014;4(7):816-27. doi:10.1158/2159-8290.CD-13-0424